InVezz – Rare disease specialist Shire Plc (LON:SHP) today rebuffed claims that it does not have grounds to maintain patents on its Lialda and Gattex medicines. The claim was made by US hedge fund Hayman Capital Management.
While acknowledging the petitions which Hayman Capital filed last week with the US Patent and Trademark Office (USPTO), Shire said in a statement that the patents “protect the innovation and value Shire brings to patients who benefit from these important medicines.”
